Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 6
2005 16
2006 29
2007 26
2008 29
2009 32
2010 22
2011 32
2012 27
2013 22
2014 30
2015 33
2016 28
2017 20
2018 34
2019 34
2020 48
2021 40
2022 43
2023 46
2024 31

Text availability

Article attribute

Article type

Publication date

Search Results

553 results

Results by year

Filters applied: . Clear all
Page 1
Insomnia Management: A Review and Update.
Shaha DP. Shaha DP. J Fam Pract. 2023 Jul;72(6 Suppl):S31-S36. doi: 10.12788/jfp.0620. J Fam Pract. 2023. PMID: 37549414 Free PMC article. Review.
Pharmacologic agents that are approved by the US Food and Drug Administration for insomnia include benzodiazepine receptor agonists (zolpidem, eszopiclone, and zaleplon), low-dose doxepin (tricyclic antidepressant), ramelteon (melatonin receptor agonist), and dual orexin r …
Pharmacologic agents that are approved by the US Food and Drug Administration for insomnia include benzodiazepine receptor agonists (zolpide …
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A. De Crescenzo F, et al. Lancet. 2022 Jul 16;400(10347):170-184. doi: 10.1016/S0140-6736(22)00878-9. Lancet. 2022. PMID: 35843245 Free article.
Benzodiazepines, eszopiclone, zolpidem, and zopiclone were more efficacious than melatonin, ramelteon, and zaleplon (SMD 0.27-0.71 [moderate to very low]). Intermediate-acting benzodiazepines, long-acting benzodiazepines, and eszopiclone had fewer discontinuations due to a …
Benzodiazepines, eszopiclone, zolpidem, and zopiclone were more efficacious than melatonin, ramelteon, and zaleplon (SMD 0.27-0.71 [m …
Menopause and Sleep Disorders.
Tandon VR, Sharma S, Mahajan A, Mahajan A, Tandon A. Tandon VR, et al. J Midlife Health. 2022 Jan-Mar;13(1):26-33. doi: 10.4103/jmh.jmh_18_22. Epub 2022 May 2. J Midlife Health. 2022. PMID: 35707298 Free PMC article. Review.
Tricyclic antidepressant, Selective Serotonin Reuptake Inhibitors (SSRI), Melatonin, Duloxetine, Fluoxetine, Imipramine, Nortriptyline or Amitriptyline and other drugs such as Eszopiclone, Escitalopram, Gabapentin, Quiteiapine, Citalopram, Mirtazapine followed by long-acting Mela …
Tricyclic antidepressant, Selective Serotonin Reuptake Inhibitors (SSRI), Melatonin, Duloxetine, Fluoxetine, Imipramine, Nortriptyline or Am …
Insomnia in Elderly Patients: Recommendations for Pharmacological Management.
Abad VC, Guilleminault C. Abad VC, et al. Drugs Aging. 2018 Sep;35(9):791-817. doi: 10.1007/s40266-018-0569-8. Drugs Aging. 2018. PMID: 30058034 Review.
This review focuses on Food and Drug Administration (FDA)-approved drugs for insomnia, including suvorexant, low-dose doxepin, Z-drugs (eszopiclone, zolpidem, zaleplon), benzodiazepines (triazolam, temazepam), and ramelteon. We review the indications, dosing, efficacy, ben …
This review focuses on Food and Drug Administration (FDA)-approved drugs for insomnia, including suvorexant, low-dose doxepin, Z-drugs (eszo …
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.
Atkin T, Comai S, Gobbi G. Atkin T, et al. Pharmacol Rev. 2018 Apr;70(2):197-245. doi: 10.1124/pr.117.014381. Pharmacol Rev. 2018. PMID: 29487083 Review.
We analyzed the melatonergic agonist drugs, agomelatine, prolonged-release melatonin, ramelteon, and tasimelteon; the dual orexin receptor antagonist suvorexant; the modulators of the alpha(2)delta subunit of voltage-sensitive calcium channels, gabapentin and pregabalin; t …
We analyzed the melatonergic agonist drugs, agomelatine, prolonged-release melatonin, ramelteon, and tasimelteon; the dual orexin rec …
Drugs for chronic insomnia.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6. doi: 10.58347/tml.2023.1667a. Med Lett Drugs Ther. 2023. PMID: 36630579 No abstract available.
Ramelteon.
[No authors listed] [No authors listed] 2022 Apr 18. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2022 Apr 18. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999812 Free Books & Documents. Review.
Data from one patient indicates that ramelteon and its principle active metabolite have low levels in milk. ...
Data from one patient indicates that ramelteon and its principle active metabolite have low levels in milk. ...
Melatonin and its analogs in insomnia and depression.
Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Cardinali DP, et al. J Pineal Res. 2012 May;52(4):365-75. doi: 10.1111/j.1600-079X.2011.00962.x. Epub 2011 Sep 23. J Pineal Res. 2012. PMID: 21951153 Free article. Review.
Thus, attention has been focused either on the development of more potent melatonin analogs with prolonged effects or on the design of slow release melatonin preparations. The MT(1) and MT(2) melatonergic receptor ramelteon was effective in increasing total sleep time and …
Thus, attention has been focused either on the development of more potent melatonin analogs with prolonged effects or on the design of slow …
Ramelteon.
[No authors listed] [No authors listed] 2018 May 21. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 May 21. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643756 Free Books & Documents. Review.
Ramelteon is a melatonin receptor agonist that is used for the treatment of insomnia. Ramelteon has not been implicated in causing serum enzyme elevations or clinically apparent liver injury....
Ramelteon is a melatonin receptor agonist that is used for the treatment of insomnia. Ramelteon has not been implicated in cau
Review of Safety and Efficacy of Sleep Medicines in Older Adults.
Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, Mergenhagen KA. Schroeck JL, et al. Clin Ther. 2016 Nov;38(11):2340-2372. doi: 10.1016/j.clinthera.2016.09.010. Epub 2016 Oct 15. Clin Ther. 2016. PMID: 27751669 Review.
Search terms included medications approved by the US Food and Drug Administration for insomnia: benzodiazepines (triazolam, estazolam, temazepam, flurazepam, and quazepam), nonbenzodiazepine receptor agonists (non-BzRAs; zaleplon, zolpidem, and eszopiclone), suvorexant, ramelt
Search terms included medications approved by the US Food and Drug Administration for insomnia: benzodiazepines (triazolam, estazolam, temaz …
553 results